Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.20 USD
Change Today -0.0207 / -9.38%
Volume 17.2K
TPI On Other Exchanges
As of 4:15 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

tianyin pharmaceutical co in (TPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/5/15 - $0.78
52 Week Low
10/14/15 - $0.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tianyin pharmaceutical co in (TPI) Related Businessweek News

No Related Businessweek News Found

tianyin pharmaceutical co in (TPI) Details

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company, develops, manufactures, markets, and sells patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and active pharmaceutical ingredients in the People’s Republic of China. It offers a portfolio of 58 products for use in the therapeutic areas of internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. The company markets its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies. Tianyin Pharmaceutical Co., Inc. was founded in 1994 and is headquartered in Chengdu, the People’s Republic of China.

1,000 Employees
Last Reported Date: 12/9/14
Founded in 1994

tianyin pharmaceutical co in (TPI) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $100.0K
Chief Operating Officer, Chief Advisor of Sal...
Total Annual Compensation: $80.0K
Chief Technology Officer
Total Annual Compensation: $80.0K
Vice President of Marketing & Sales
Total Annual Compensation: $80.0K
Compensation as of Fiscal Year 2014.

tianyin pharmaceutical co in (TPI) Key Developments

Tianyin Pharmaceutical Co., Inc. announced delayed 10-Q filing

On 11/17/2015, Tianyin Pharmaceutical Co., Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Tianyin Pharmaceutical Inc. Receives Non-Compliance Notice From NYSE MKT LLC

Tianyin Pharmaceutical Inc. received notice on October 16, 2015 from the NYSE MKT LLC indicating that the company is below certain of the Exchange’s continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Annual Report on Form 10-K for the year ended June 30, 2015. Under NYSE MKT rules, until the company files the Form 10-K, its common stock will remain listed on the NYSE MKT under the symbol ‘TPI’, but will be assigned an ‘.LF’ indicator to signify late filing status. Five business days following the receipt of the noncompliance letter, the company will be added to the list of NYSE MKT noncompliant issuers on the website and the indicator will be disseminated with the company’s ticker symbol. The indicator will be removed when the company has regained compliance with all applicable continued listing standards. In order to maintain its listing, the company must submit a plan of compliance by November 15, 2015 addressing how it intends to regain compliance with Sections 134 and 1101 of the NYSE MKT Company Guide by April 15, 2016. If the plan is accepted, the company may be able to continue its listing but will be subject to periodic reviews by the Exchange. If the plan is not accepted or if it is accepted but the company is not in compliance with the continued listing standards by April 15, 2016, or if the company does not make progress consistent with the plan, the Exchange will initiate delisting procedures as appropriate. The company intends to submit a compliance plan on or before the deadline set by the Exchange. Currently the company is working diligently to compile and disseminate the information required to be included in the Form 10-K. The company expects to file the Form 10-K before the deadline set by the Exchange.

Tianyin Pharmaceutical Co., Inc. announced delayed annual 10-K filing

On 09/28/2015, Tianyin Pharmaceutical Co., Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TPI:US $0.20 USD -0.0207

TPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ImmunoCellular Therapeutics Ltd $0.45 USD +0.0209
Northwest Biotherapeutics Inc $4.70 USD -0.27
Opexa Therapeutics Inc $4.09 USD +0.22
StemCells Inc $0.54 USD +0.0194
View Industry Companies

Industry Analysis


Industry Average

Valuation TPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 0.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TIANYIN PHARMACEUTICAL CO IN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at